Skolarus, Ted A.
Hawley, Sarah T.
Wittmann, Daniela A.
Forman, Jane
Metreger, Tabitha
Sparks, Jordan B.
Zhu, Kevin
Caram, Megan E. V.
Hollenbeck, Brent K.
Makarov, Danil V.
Leppert, John T.
Shelton, Jeremy B.
Shahinian, Vahakn
Srinivasaraghavan, Sriram
Sales, Anne E.
Funding for this research was provided by:
National Cancer Institute (R37 CA222885)
Article History
Received: 8 October 2018
Accepted: 30 October 2018
First Online: 29 November 2018
Ethics approval and consent to participate
: This study has been approved by the VA Ann Arbor Healthcare System IRB (IRB-2017-1047) and the University of Michigan IRB (HUM00133932). As this study is conducted solely by phone and by mail and is considered minimal risk, a waiver of documentation of signed informed consent and HIPAA Authorization was approved. Verbal informed consent is obtained for all patients participating in the research. Further information and documentation on IRB approval is available upon request.
: Not applicable.
: The authors declare that they have no competing interests. Dr. Skolarus is a prostate cancer survivorship author for UpToDateā¢.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.